Udvalget for Humanmedicinske Lægemidler (CHMP) konstaterede, at patienter med "stort behov" havde psoriasis i sværere grad, og at virkningen af Raptiva er relevant for sådanne patienter.
The Committee for Medicinal products for Human Use (CHMP) noted that psoriasis was more severe in ‘ high-need’ patients, and that the effectiveness of Raptiva is relevant for these patients.